Bukwang Pharmaceutical Overview
- Year Founded
-
1960
- Status
-
Public
- Employees
-
611
- Stock Symbol
-
003000
- Investments
-
12
- Share Price
-
$2.95
- (As of Thursday Closing)
Bukwang Pharmaceutical General Information
Description
Bukwang Pharmaceutical Co Ltd manufactures and markets pharmaceutical medicines. The Company's products are Dexid, Ferrova, Legaron, Thioctacid, Synthroid Latuda, Tarsenol, Orfil, Axima, Hexamedine, Dilastin Endoxan, Sirinmed, Bukwangtax, Antiplague, and others.
Contact Information
Website
www.bukwang.co.krCorporate Office
- 7, Sangdo-ro
- Dongjak-gu
- Seoul, 06955
- South Korea
Corporate Office
- 7, Sangdo-ro
- Dongjak-gu
- Seoul, 06955
- South Korea
Bukwang Pharmaceutical Stock Performance
As of 12-Nov-2026, Bukwang Pharmaceutical’s stock price is $2.95. Its current market cap is $292M with 98.7M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.95 | $3.03 | $2.42 - $6.55 | $292M | 98.7M | 415K | $0.06 |
Bukwang Pharmaceutical Financials Summary
As of 30-Jun-2026, Bukwang Pharmaceutical has a trailing 12-month revenue of $148M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 190,405 | 164,514 | 190,128 | 284,311 |
| Revenue | 148,212 | 141,036 | 117,328 | 96,316 |
| EBITDA | 9,124 | 7,771 | 2,351 | (26,425) |
| Net Income | 6,049 | 8,824 | (1,936) | (23,962) |
| Total Assets | 302,687 | 330,758 | 253,352 | 332,912 |
| Total Debt | 52,279 | 55,792 | 53,921 | 61,603 |
Bukwang Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bukwang Pharmaceutical Patents
Bukwang Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023224358-A1 | Soft capsule having improved pharmaceutical stability | Inactive | 18-May-2022 | ||
| WO-2021182685-A1 | Use of l-nucleoside for treating coronavirus | Inactive | 10-Mar-2020 | ||
| JP-2021513506-A | How to prepare large-scale trimidone | Active | 11-Jan-2018 | ||
| JP-7033662-B2 | How to prepare large-scale trimidone | Active | 11-Jan-2018 | ||
| AU-2018401298-A1 | Method for preparing tolimidone on large scale | Active | 11-Jan-2018 | C07D239/52 |
Bukwang Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Bukwang Pharmaceutical Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bukwang Pharmaceutical Investments & Acquisitions (12)
Bukwang Pharmaceutical’s most recent deal was a Merger/Acquisition with Bukwang Unipharma for . The deal was made on 27-May-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Bukwang Unipharma | 27-May-2026 | Merger/Acquisition | Pharmaceuticals | ||
| Contera Pharma | 01-Jun-2025 | Secondary Transaction - Private | Drug Discovery | ||
| ImmPACT Bio | 01-Apr-2024 | Later Stage VC | Drug Discovery | ||
| ProteKt Therapeutics | 26-Jan-2023 | Merger/Acquisition | Drug Discovery | ||
| Jaguahr Therapeutics | 28-Apr-2021 | Merger/Acquisition | Drug Discovery |
Bukwang Pharmaceutical ESG
Risk Overview
Risk Rating
Updated September, 30, 2025
37.01 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Pharmaceuticals
Subindustry
of 435
Rank
Percentile
Bukwang Pharmaceutical Exits (3)
Bukwang Pharmaceutical’s most recent exit was on 01-Apr-2024 from ImmPACT Bio. The exit was categorized as with 9 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| ImmPACT Bio | 01-Apr-2024 | Completed |
|
||
| ImmPACT Bio | 18-Aug-2020 | Completed |
|
||
| Acer Therapeutics | 05-May-2016 | Later Stage VC | Completed |
|
Bukwang Pharmaceutical Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Jaguahr Therapeutics | Singapore, Singapore | 2019 | |
| ProteKt Therapeutics | Beni-Brak, Israel | 2014 | |
| Contera Pharma | Horsholm, Denmark | 2010 |
Bukwang Pharmaceutical FAQs
-
When was Bukwang Pharmaceutical founded?
Bukwang Pharmaceutical was founded in 1960.
-
Where is Bukwang Pharmaceutical headquartered?
Bukwang Pharmaceutical is headquartered in Seoul, South Korea.
-
What is the size of Bukwang Pharmaceutical?
Bukwang Pharmaceutical has 611 total employees.
-
What industry is Bukwang Pharmaceutical in?
Bukwang Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is Bukwang Pharmaceutical a private or public company?
Bukwang Pharmaceutical is a Public company.
-
What is Bukwang Pharmaceutical’s stock symbol?
The ticker symbol for Bukwang Pharmaceutical is 003000.
-
What is the current stock price of Bukwang Pharmaceutical?
As of 12-Nov-2026 the stock price of Bukwang Pharmaceutical is $2.95.
-
What is the current market cap of Bukwang Pharmaceutical?
The current market capitalization of Bukwang Pharmaceutical is $292M.
-
What is Bukwang Pharmaceutical’s current revenue?
The trailing twelve month revenue for Bukwang Pharmaceutical is $148M.
-
What is Bukwang Pharmaceutical’s annual earnings per share (EPS)?
Bukwang Pharmaceutical’s EPS for 12 months was $0.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
